In terms of outcomes, the DKCRUSH-V trial reported a lower rate of the composite endpoint of cardiac death, target vessel MI, or clinically driven TLR, whereas the EBC-MAIN trial showed numerically fewer major adverse cardiovascular events (MACE) in a stepwise layered provisional approach, although this did not reach statistical significance.
1
—
—